Compare · LGND vs NVO
LGND vs NVO
Side-by-side comparison of Ligand Pharmaceuticals Incorporated (LGND) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LGND and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 40.4x LGND ($4.75B).
- Over the past year, LGND is up 116.6% and NVO is down 43.1% - LGND leads by 159.7 points.
- NVO has been more active in the news (7 items in the past 4 weeks vs 5 for LGND).
- NVO has more recent analyst coverage (25 ratings vs 9 for LGND).
- Company
- Ligand Pharmaceuticals Incorporated
- Novo Nordisk A/S
- Price
- $237.54+0.65%
- $42.94-1.84%
- Market cap
- $4.75B
- $191.82B
- 1M return
- +2.46%
- -6.14%
- 1Y return
- +116.58%
- -43.10%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 5
- 7
- Recent ratings
- 9
- 25
Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LGND
- CLO & Secretary Reardon Andrew sold $1,135,316 worth of shares (5,000 units at $227.06) as part of a pre-agreed trading plan and exercised 5,000 shares at a strike of $52.27 (SEC Form 4)
- Chief Financial Officer Espinoza Octavio exercised 1,736 shares at a strike of $57.58, increasing direct ownership by 7% to 27,679 units (SEC Form 4)
- Ligand to Participate in June Investor Conferences
- SEC Form DEFA14A filed by Ligand Pharmaceuticals Incorporated
- SEC Form 8-K filed by Ligand Pharmaceuticals Incorporated
- Director Kozarich John W sold $563,080 worth of shares (2,501 units at $225.14) as part of a pre-agreed trading plan and exercised 2,034 shares at a strike of $69.51, decreasing direct ownership by 1% to 41,786 units (SEC Form 4)
- SEC Form 144 filed by Ligand Pharmaceuticals Incorporated
- Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
- SEC Form 10-Q filed by Ligand Pharmaceuticals Incorporated
- Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates